You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFesoterodine
Accession NumberDB06702
TypeSmall Molecule
GroupsApproved
DescriptionFesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.
Structure
Thumb
Synonyms
FESO
Fesoterodine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ToviazProlonged-release tablet8 mgOral usePfizer Limited2007-04-20Not applicableEu
Toviaztablet, film coated, extended release4 mg/1oralU.S. Pharmaceuticals2008-10-31Not applicableUs
ToviazProlonged-release tablet4 mgOral usePfizer Limited2007-04-20Not applicableEu
ToviazProlonged-release tablet8 mgOral usePfizer Limited2007-04-20Not applicableEu
Toviaztablet, film coated, extended release4 mg/1oralPfizer Laboratories Div Pfizer Inc2008-10-31Not applicableUs
ToviazProlonged-release tablet8 mgOral usePfizer Limited2007-04-20Not applicableEu
ToviazProlonged-release tablet4 mgOral usePfizer Limited2007-04-20Not applicableEu
ToviazProlonged-release tablet8 mgOral usePfizer Limited2007-04-20Not applicableEu
Toviaztablet, film coated, extended release4 mg/1oralCardinal Health2008-10-31Not applicableUs
ToviazProlonged-release tablet4 mgOral usePfizer Limited2007-04-20Not applicableEu
Toviaztablet, film coated, extended release4 mg/1oralAvera Mc Kennan Hospital2015-04-01Not applicableUs
ToviazProlonged-release tablet8 mgOral usePfizer Limited2007-04-20Not applicableEu
Toviaztablet, film coated, extended release8 mg/1oralPfizer Laboratories Div Pfizer Inc2008-10-31Not applicableUs
ToviazProlonged-release tablet4 mgOral usePfizer Limited2007-04-20Not applicableEu
ToviazProlonged-release tablet4 mgOral usePfizer Limited2007-04-20Not applicableEu
ToviazProlonged-release tablet8 mgOral usePfizer Limited2007-04-20Not applicableEu
Toviaztablet, film coated, extended release8 mg/1oralCardinal Health2008-10-31Not applicableUs
Toviaztablet (extended-release)4 mgoralPfizer Canada Inc2012-04-19Not applicableCanada
ToviazProlonged-release tablet4 mgOral usePfizer Limited2007-04-20Not applicableEu
Toviaztablet, film coated, extended release4 mg/1oralPhysicians Total Care, Inc.2010-08-23Not applicableUs
ToviazProlonged-release tablet8 mgOral usePfizer Limited2007-04-20Not applicableEu
ToviazProlonged-release tablet8 mgOral usePfizer Limited2007-04-20Not applicableEu
ToviazProlonged-release tablet4 mgOral usePfizer Limited2007-04-20Not applicableEu
ToviazProlonged-release tablet4 mgOral usePfizer Limited2007-04-20Not applicableEu
Toviaztablet, film coated, extended release8 mg/1oralU.S. Pharmaceuticals2008-10-31Not applicableUs
ToviazProlonged-release tablet8 mgOral usePfizer Limited2007-04-20Not applicableEu
Toviaztablet (extended-release)8 mgoralPfizer Canada Inc2012-04-19Not applicableCanada
ToviazProlonged-release tablet8 mgOral usePfizer Limited2007-04-20Not applicableEu
Toviaztablet, film coated, extended release8 mg/1oralPhysicians Total Care, Inc.2010-09-15Not applicableUs
ToviazProlonged-release tablet4 mgOral usePfizer Limited2007-04-20Not applicableEu
ToviazProlonged-release tablet4 mgOral usePfizer Limited2007-04-20Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Fesoterodine fumarate
286930-03-8
Thumb
  • InChI Key: MWHXMIASLKXGBU-RNCYCKTQSA-N
  • Monoisotopic Mass: 527.288302671
  • Average Mass: 527.649
DBSALT000085
Categories
UNII621G617227
CAS number286930-02-7
WeightAverage: 411.5769
Monoisotopic: 411.277344055
Chemical FormulaC26H37NO3
InChI KeyInChIKey=DCCSDBARQIPTGU-HSZRJFAPSA-N
InChI
InChI=1S/C26H37NO3/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3/t23-/m1/s1
IUPAC Name
2-[(1R)-3-[bis(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-methylpropanoate
SMILES
CC(C)N(CC[[email protected]](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Phenylpropylamine
  • Phenol ester
  • Benzyl alcohol
  • Aralkylamine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
PharmacodynamicsFesoterodine is a prodrug. In-vivo it is broken down into its active metabolite, 5-hydroxymethyl tolterodine (5-HMT), by plasma esterases. The 5-hydroxymethyl metabolite, which exhibits an antimuscarinic activity. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. Therefore, acting as a competitive muscarinic receptor antagonist, fesoterodine ultimately acts to decrease the detrusor pressure by its muscarinic antagonism, thereby decreasing bladder contraction and consequently, the urge to urinate.
Mechanism of actionFesoterodine, once converted to its active metabolite, 5-hydroxymethyltolterodine, acts as a competitive antagonists at muscarinic receptors. This results in the inhibition of bladder contraction, decrease in detrusor pressure, and an incomplete emptying of the bladder.
Related Articles
AbsorptionTmax (5-HMT): 5 hours post-adminitration of fesoterodine. AUC (0,∞)= 49.5 ng·h/ ml Bioavailability, 5-HMT = 52%
Volume of distribution

IV, 5-HMT: 169 L

Protein binding5-HMT: 50% to albumin and alpha1-acid glycoprotein
Metabolism

Metabolized by ubiquitous, nonspecific esterases to transform fesoterodine into 5-HMT Extensive metabolism via CYP2D6 and CYP3A4 into inactive metabolites

Route of eliminationRenal: 70% of fesoterodine was recovered in urine as 5-HMT; 35% carboxy metabolite; 18% carboxy-N-desisopropylmetabolite, and 1% N-desisopropyl metabolite Fecal: 7% Hepatic: fesoterodine elimination via CYP2D6 and CYP3A4
Half life7-8 hours for the active metabolite 5-hydroxymethyl tolterodine
Clearance

5-HMT, healthy subjects: 14.4 L/h
5-HMT is also secreted into the nephron.

ToxicityRat, Oral, LD50: ~ 681 mg/kg Mouse, Oral, LD50: ~ 316 mg/kg Rat, Intravenous, NOAEL: 10 mg/kg Mouse, Intravenous, NOAEL: 10 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9535
Blood Brain Barrier+0.5648
Caco-2 permeable+0.7699
P-glycoprotein substrateSubstrate0.5268
P-glycoprotein inhibitor INon-inhibitor0.5556
P-glycoprotein inhibitor IINon-inhibitor0.625
Renal organic cation transporterInhibitor0.6025
CYP450 2C9 substrateNon-substrate0.6853
CYP450 2D6 substrateNon-substrate0.5151
CYP450 3A4 substrateSubstrate0.5939
CYP450 1A2 substrateInhibitor0.6306
CYP450 2C9 inhibitorNon-inhibitor0.7227
CYP450 2D6 inhibitorInhibitor0.6255
CYP450 2C19 inhibitorNon-inhibitor0.7334
CYP450 3A4 inhibitorNon-inhibitor0.5718
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6144
Ames testNon AMES toxic0.646
CarcinogenicityNon-carcinogens0.7213
BiodegradationNot ready biodegradable0.9385
Rat acute toxicity2.4003 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9196
hERG inhibition (predictor II)Inhibitor0.5602
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Prolonged-release tabletOral use4 mg
Prolonged-release tabletOral use8 mg
Tablet (extended-release)oral4 mg
Tablet (extended-release)oral8 mg
Tablet, film coated, extended releaseoral4 mg/1
Tablet, film coated, extended releaseoral8 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6858650 No2002-07-032022-07-03Us
US7384980 No1999-05-112019-05-11Us
US7807715 No2007-06-072027-06-07Us
US7855230 No1999-05-112019-05-11Us
US7985772 No1999-05-112019-05-11Us
US8088398 No2007-06-072027-06-07Us
US8338478 No1999-05-112019-05-11Us
US8501723 No2007-06-072027-06-07Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityHighly soluble MSDS
Predicted Properties
PropertyValueSource
Water Solubility0.00205 mg/mLALOGPS
logP5.45ALOGPS
logP5.7ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)14.98ChemAxon
pKa (Strongest Basic)10.64ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.77 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity124.08 m3·mol-1ChemAxon
Polarizability48.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Claus Meese, “CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF.” U.S. Patent US20090192224, issued July 30, 2009.

US20090192224
General References
  1. Malhotra B, Dickins M, Alvey C, Jumadilova Z, Li X, Duczynski G, Gandelman K: Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9. doi: 10.1111/j.1365-2125.2011.04007.x. [PubMed:21545485 ]
  2. Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC: The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem. 2009;16(33):4481-9. [PubMed:19835561 ]
External Links
ATC CodesG04BD11
AHFS Codes
  • 12:08.08
PDB EntriesNot Available
FDA labelDownload (430 KB)
MSDSDownload (102 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with 1,10-Phenanthroline.
AbirateroneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Abiraterone.
AcebutololThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Acebutolol.
AcetaminophenThe serum concentration of Fesoterodine can be increased when it is combined with Acetaminophen.
AclidiniumAclidinium may increase the anticholinergic activities of Fesoterodine.
AclidiniumThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Aclidinium.
AfatinibThe serum concentration of Fesoterodine can be increased when it is combined with Afatinib.
AjmalineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ajmaline.
AlbendazoleThe serum concentration of Fesoterodine can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Fesoterodine can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Fesoterodine can be increased when it is combined with Alectinib.
AlfentanilThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Alfentanil.
AlfentanilThe serum concentration of Fesoterodine can be increased when it is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Alphacetylmethadol.
AmantadineThe serum concentration of Fesoterodine can be increased when it is combined with Amantadine.
AmbenoniumThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Ambenonium.
Aminohippuric acidThe serum concentration of Fesoterodine can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amiodarone.
AmitriptylineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amitriptyline.
AmlodipineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amlodipine.
AmodiaquineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amodiaquine.
AmphetamineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amphetamine.
AmprenavirThe serum concentration of Fesoterodine can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Fesoterodine can be increased when it is combined with Amsacrine.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Fesoterodine.
AntipyrineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Antipyrine.
AprepitantThe serum concentration of Fesoterodine can be increased when it is combined with Aprepitant.
AripiprazoleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Aripiprazole.
ArtemetherThe metabolism of Fesoterodine can be decreased when combined with Artemether.
AsenapineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Asenapine.
AstemizoleThe serum concentration of Fesoterodine can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Fesoterodine can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Fesoterodine can be increased when it is combined with Atenolol.
AtomoxetineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Atomoxetine.
AtorvastatinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Atorvastatin.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Fesoterodine.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Fesoterodine.
AzelastineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Azelastine.
AzithromycinThe serum concentration of Fesoterodine can be increased when it is combined with Azithromycin.
BenactyzineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Benactyzine.
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Fesoterodine.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Fesoterodine.
BenzocaineThe serum concentration of Fesoterodine can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Fesoterodine can be increased when it is combined with Bepridil.
BetaxololThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Betaxolol.
BexaroteneThe serum concentration of Fesoterodine can be decreased when it is combined with Bexarotene.
BezitramideThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Bezitramide.
BicalutamideThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Bicalutamide.
BiperidenThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Biperiden.
BiperidenThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Biperiden.
BoceprevirThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Boceprevir.
BortezomibThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Bortezomib.
BosentanThe serum concentration of Fesoterodine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Fesoterodine can be increased when it is combined with Bosutinib.
Botulinum Toxin Type AFesoterodine may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BFesoterodine may increase the anticholinergic activities of Botulinum Toxin Type B.
BromocriptineThe serum concentration of Fesoterodine can be increased when it is combined with Bromocriptine.
BrompheniramineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Brompheniramine.
BuprenorphineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Buprenorphine.
BupropionThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Bupropion.
BuspironeThe serum concentration of Fesoterodine can be increased when it is combined with Buspirone.
ButorphanolThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Butorphanol.
CabazitaxelThe serum concentration of Fesoterodine can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Fesoterodine can be increased when it is combined with Caffeine.
CanagliflozinThe serum concentration of Fesoterodine can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Fesoterodine can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Fesoterodine can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Fesoterodine can be decreased when it is combined with Carbamazepine.
CarbinoxamineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Carfentanil.
CarteololThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Carteolol.
CarvedilolThe serum concentration of Fesoterodine can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Fesoterodine can be increased when it is combined with Caspofungin.
CelecoxibThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Celecoxib.
CeritinibThe serum concentration of Fesoterodine can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cerivastatin.
ChloroquineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Chloroquine.
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Fesoterodine.
ChlorphenamineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Chlorphenoxamine.
ChlorpromazineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Chlorpromazine.
ChlorpropamideThe serum concentration of Fesoterodine can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Fesoterodine can be increased when it is combined with Chlorprothixene.
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Fesoterodine.
CholecalciferolThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cholecalciferol.
CholesterolThe serum concentration of Fesoterodine can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Fesoterodine can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Fesoterodine can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cimetidine.
CimetropiumFesoterodine may increase the anticholinergic activities of Cimetropium.
CinacalcetThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cinacalcet.
CiprofloxacinThe serum concentration of Fesoterodine can be increased when it is combined with Ciprofloxacin.
CisaprideThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cisapride.
CitalopramThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Citalopram.
ClarithromycinThe serum concentration of Fesoterodine can be increased when it is combined with Clarithromycin.
ClemastineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clemastine.
ClobazamThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clobazam.
ClofazimineThe serum concentration of Fesoterodine can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clomipramine.
ClotrimazoleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clotrimazole.
ClozapineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clozapine.
CobicistatThe serum concentration of Fesoterodine can be increased when it is combined with Cobicistat.
CocaineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cocaine.
CodeineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Codeine.
CodeineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Codeine.
ColchicineThe serum concentration of Fesoterodine can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Fesoterodine can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Fesoterodine can be increased when it is combined with Conivaptan.
CoumaphosThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Coumaphos.
CrizotinibThe metabolism of Fesoterodine can be decreased when combined with Crizotinib.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Fesoterodine.
CyclophosphamideThe serum concentration of Fesoterodine can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cyclosporine.
DabrafenibThe serum concentration of Fesoterodine can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Fesoterodine can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Fesoterodine can be increased when it is combined with Dactinomycin.
DarifenacinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Darifenacin.
DarifenacinThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Darifenacin.
DarunavirThe serum concentration of Fesoterodine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Fesoterodine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Fesoterodine can be decreased when it is combined with Daunorubicin.
DecamethoniumThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Decamethonium.
DeferasiroxThe serum concentration of Fesoterodine can be decreased when it is combined with Deferasirox.
DelavirdineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Delavirdine.
DemecariumThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Demecarium.
DesipramineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desipramine.
DesloratadineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desloratadine.
DesloratadineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Desloratadine.
DexamethasoneThe serum concentration of Fesoterodine can be decreased when it is combined with Dexamethasone.
DexetimideThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Dexetimide.
DexfenfluramineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dexfenfluramine.
DexmedetomidineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dexmedetomidine.
DexmethylphenidateThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dexmethylphenidate.
DextroamphetamineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dextroamphetamine.
DextromethorphanThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dextromethorphan.
DextromoramideThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Dextromoramide.
DextropropoxypheneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dextropropoxyphene.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Dezocine.
DichlorvosThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Dichlorvos.
DiclofenacThe serum concentration of Fesoterodine can be increased when it is combined with Diclofenac.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Fesoterodine.
DigoxinThe serum concentration of Fesoterodine can be decreased when it is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Fesoterodine can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Dihydromorphine.
DiltiazemThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Diltiazem.
Dimethyl sulfoxideThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dimethyl sulfoxide.
DiphenhydramineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Diphenoxylate.
DipyridamoleThe serum concentration of Fesoterodine can be increased when it is combined with Dipyridamole.
DonepezilThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Donepezil.
DoxazosinThe serum concentration of Fesoterodine can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Doxepin.
DoxorubicinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Doxorubicin.
DoxycyclineThe metabolism of Fesoterodine can be decreased when combined with Doxycycline.
DPDPEThe risk or severity of adverse effects can be increased when Fesoterodine is combined with DPDPE.
DronabinolFesoterodine may increase the tachycardic activities of Dronabinol.
DronabinolThe serum concentration of Fesoterodine can be increased when it is combined with Dronabinol.
DronedaroneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dronedarone.
DuloxetineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Duloxetine.
EchothiophateThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Echothiophate.
EdrophoniumThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Edrophonium.
EfavirenzThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Efavirenz.
ElbasvirThe serum concentration of Fesoterodine can be increased when it is combined with Elbasvir.
EliglustatThe metabolism of Fesoterodine can be decreased when combined with Eliglustat.
EluxadolineFesoterodine may increase the constipating activities of Eluxadoline.
EnalaprilThe serum concentration of Fesoterodine can be increased when it is combined with Enalapril.
EnzalutamideThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Enzalutamide.
EpinastineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Epinastine.
ErgonovineThe serum concentration of Fesoterodine can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Fesoterodine can be increased when it is combined with Ergotamine.
ErythromycinThe metabolism of Fesoterodine can be decreased when combined with Erythromycin.
EscitalopramThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Fesoterodine can be decreased when it is combined with Eslicarbazepine acetate.
EstramustineThe serum concentration of Fesoterodine can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Fesoterodine can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Fesoterodine can be decreased when it is combined with Estrone.
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Fesoterodine.
EthylmorphineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Ethylmorphine.
EtoposideThe serum concentration of Fesoterodine can be increased when it is combined with Etoposide.
EtoricoxibThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Etoricoxib.
EtorphineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Etorphine.
EtravirineThe serum concentration of Fesoterodine can be decreased when it is combined with Etravirine.
FelodipineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Felodipine.
FenfluramineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Fentanyl.
FentanylThe serum concentration of Fesoterodine can be increased when it is combined with Fentanyl.
FenthionThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Fenthion.
FexofenadineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fexofenadine.
FidaxomicinThe serum concentration of Fesoterodine can be increased when it is combined with Fidaxomicin.
FlecainideThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Flecainide.
FluconazoleThe metabolism of Fesoterodine can be decreased when combined with Fluconazole.
FluoxetineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluoxetine.
FlupentixolThe serum concentration of Fesoterodine can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluphenazine.
FlurazepamThe serum concentration of Fesoterodine can be increased when it is combined with Flurazepam.
FluvastatinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluvastatin.
FluvoxamineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluvoxamine.
FosamprenavirThe metabolism of Fesoterodine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Fesoterodine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Fesoterodine can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Fesoterodine can be increased when it is combined with Fusidic Acid.
GalantamineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Fesoterodine.
GefitinibThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Gefitinib.
GenisteinThe serum concentration of Fesoterodine can be increased when it is combined with Genistein.
Ginkgo bilobaThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Glucagon recombinant.
GlyburideThe serum concentration of Fesoterodine can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Fesoterodine can be increased when it is combined with Glycerol.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Fesoterodine.
GlycopyrroniumFesoterodine may increase the anticholinergic activities of Glycopyrronium.
Gramicidin DThe serum concentration of Fesoterodine can be increased when it is combined with Gramicidin D.
GranisetronThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Granisetron.
GrepafloxacinThe serum concentration of Fesoterodine can be increased when it is combined with Grepafloxacin.
HalofantrineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Halofantrine.
HaloperidolThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Haloperidol.
HeroinThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Hexamethonium.
Histamine PhosphateThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Histamine Phosphate.
HomatropineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Homatropine.
Huperzine AThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Huperzine A.
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Fesoterodine.
HydrocodoneThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Hydrocodone.
HydrocortisoneThe serum concentration of Fesoterodine can be increased when it is combined with Hydrocortisone.
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Fesoterodine.
HydromorphoneThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Hydromorphone.
HydroxychloroquineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxychloroquine.
HydroxyureaThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxyurea.
HydroxyzineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Fesoterodine.
IdarubicinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Idarubicin.
IdelalisibThe serum concentration of Fesoterodine can be increased when it is combined with Idelalisib.
ImatinibThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Imatinib.
ImipramineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Imipramine.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Fesoterodine.
IndinavirThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Indinavir.
indisulamThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with indisulam.
IndomethacinThe serum concentration of Fesoterodine can be increased when it is combined with Indomethacin.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Fesoterodine.
IrbesartanThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Irbesartan.
IsavuconazoniumThe metabolism of Fesoterodine can be decreased when combined with Isavuconazonium.
IsoflurophateThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Isoflurophate.
IsoniazidThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Isoniazid.
IsradipineThe metabolism of Fesoterodine can be decreased when combined with Isradipine.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Fesoterodine.
ItraconazoleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Itraconazole.
IvacaftorThe serum concentration of Fesoterodine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Fesoterodine can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Fesoterodine can be increased when it is combined with Ketamine.
KetobemidoneThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Ketobemidone.
KetoconazoleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ketoconazole.
LabetalolThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Labetalol.
LansoprazoleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lansoprazole.
LapatinibThe serum concentration of Fesoterodine can be increased when it is combined with Lapatinib.
LercanidipineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lercanidipine.
LevofloxacinThe serum concentration of Fesoterodine can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Levomethadyl Acetate.
LevorphanolThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Levorphanol.
LevothyroxineThe serum concentration of Fesoterodine can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lidocaine.
LiothyronineThe serum concentration of Fesoterodine can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Fesoterodine can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Fesoterodine can be increased when it is combined with Lisinopril.
LofentanilThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Lofentanil.
LomitapideThe serum concentration of Fesoterodine can be increased when it is combined with Lomitapide.
LomustineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lomustine.
LoperamideThe serum concentration of Fesoterodine can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lopinavir.
LoratadineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Loratadine.
LorcaserinThe metabolism of Fesoterodine can be decreased when combined with Lorcaserin.
LosartanThe serum concentration of Fesoterodine can be increased when it is combined with Losartan.
LovastatinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lovastatin.
LuliconazoleThe serum concentration of Fesoterodine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Fesoterodine can be decreased when it is combined with Lumacaftor.
LumefantrineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lumefantrine.
MalathionThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Malathion.
MaprotilineThe serum concentration of Fesoterodine can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Fesoterodine can be increased when it is combined with Mebendazole.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Fesoterodine.
MefloquineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mefloquine.
Megestrol acetateThe serum concentration of Fesoterodine can be increased when it is combined with Megestrol acetate.
MemantineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Memantine.
MeprobamateThe serum concentration of Fesoterodine can be increased when it is combined with Meprobamate.
MepyramineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mepyramine.
MethadoneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Methadyl Acetate.
MethamphetamineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methamphetamine.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Fesoterodine.
MethazolamideThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methazolamide.
MethimazoleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methimazole.
MethotrimeprazineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methotrimeprazine.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Fesoterodine.
MethylnaltrexoneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methylnaltrexone.
MethylphenidateThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methylphenidate.
MetixeneThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Metixene.
MetoclopramideThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Metoclopramide.
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Fesoterodine.
MetoprololThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Metoprolol.
MianserinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mianserin.
MibefradilThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mibefradil.
MiconazoleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Miconazole.
MidazolamThe serum concentration of Fesoterodine can be decreased when it is combined with Midazolam.
MidodrineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Midodrine.
MifepristoneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mifepristone.
MinaprineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Minaprine.
MirabegronThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mirabegron.
MirabegronThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Mirabegron.
MirtazapineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mirtazapine.
MitomycinThe serum concentration of Fesoterodine can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Fesoterodine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Fesoterodine can be decreased when it is combined with Mitoxantrone.
MoclobemideThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Moclobemide.
ModafinilThe serum concentration of Fesoterodine can be decreased when it is combined with Modafinil.
MorphineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Morphine.
MorphineThe serum concentration of Fesoterodine can be increased when it is combined with Morphine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Fesoterodine is combined with N-butylscopolammonium bromide.
NabiloneFesoterodine may increase the tachycardic activities of Nabilone.
NafcillinThe serum concentration of Fesoterodine can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Nalbuphine.
NaloxegolThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Naloxegol.
NaltrexoneThe serum concentration of Fesoterodine can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Fesoterodine can be increased when it is combined with Naringenin.
NefazodoneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nefazodone.
NelfinavirThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nelfinavir.
NeostigmineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Neostigmine.
NetupitantThe serum concentration of Fesoterodine can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nevirapine.
NiacinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Niacin.
NicardipineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nicardipine.
NicotinamideThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nicotinamide.
NifedipineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nifedipine.
NilotinibThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nilotinib.
NisoldipineThe serum concentration of Fesoterodine can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Fesoterodine can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Fesoterodine can be increased when it is combined with Nitrendipine.
NorethisteroneThe serum concentration of Fesoterodine can be decreased when it is combined with Norethisterone.
NormethadoneThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Normethadone.
NortriptylineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Fesoterodine.
OlanzapineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Olanzapine.
OlaparibThe metabolism of Fesoterodine can be decreased when combined with Olaparib.
OmeprazoleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Omeprazole.
OndansetronThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Opium.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fesoterodine.
OsimertinibThe serum concentration of Fesoterodine can be increased when it is combined with Osimertinib.
OxamniquineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Oxamniquine.
OxprenololThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Oxprenolol.
OxybutyninThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Oxybutynin.
OxybutyninThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Oxycodone.
OxymetholoneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Oxymetholone.
OxymorphoneThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Fesoterodine.
P-NitrophenolThe serum concentration of Fesoterodine can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Fesoterodine can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Fesoterodine can be increased when it is combined with Palbociclib.
Palmitic AcidThe serum concentration of Fesoterodine can be increased when it is combined with Palmitic Acid.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Fesoterodine.
PanobinostatThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Panobinostat.
PantoprazoleThe serum concentration of Fesoterodine can be increased when it is combined with Pantoprazole.
ParoxetineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Fesoterodine can be decreased when it is combined with Peginterferon alfa-2b.
PentazocineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Pentazocine.
PentobarbitalThe metabolism of Fesoterodine can be increased when combined with Pentobarbital.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Fesoterodine.
PergolideThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pergolide.
PerhexilineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Perhexiline.
PerindoprilThe serum concentration of Fesoterodine can be increased when it is combined with Perindopril.
PerphenazineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Pethidine.
PhenobarbitalThe serum concentration of Fesoterodine can be decreased when it is combined with Phenobarbital.
PhentermineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Phentermine.
PhenytoinThe metabolism of Fesoterodine can be increased when combined with Phenytoin.
PhysostigmineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Physostigmine.
PimozideThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pimozide.
PindololThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pindolol.
PioglitazoneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pioglitazone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Fesoterodine.
PipotiazineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Fesoterodine.
Platelet Activating FactorThe serum concentration of Fesoterodine can be decreased when it is combined with Platelet Activating Factor.
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Fesoterodine.
PonatinibThe serum concentration of Fesoterodine can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Fesoterodine can be increased when it is combined with Posaconazole.
Potassium ChlorideFesoterodine may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Fesoterodine.
PravastatinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pravastatin.
PraziquantelThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Praziquantel.
PrazosinThe serum concentration of Fesoterodine can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Fesoterodine can be increased when it is combined with Prednisone.
PrimaquineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Primaquine.
PrimidoneThe metabolism of Fesoterodine can be increased when combined with Primidone.
ProbenecidThe serum concentration of Fesoterodine can be increased when it is combined with Probenecid.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Fesoterodine.
ProgesteroneThe serum concentration of Fesoterodine can be decreased when it is combined with Progesterone.
ProguanilThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Proguanil.
PromazineThe metabolism of Fesoterodine can be decreased when combined with Promazine.
PromethazineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Promethazine.
PropafenoneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Propafenone.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Fesoterodine.
PropofolThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Propofol.
PropranololThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Propranolol.
ProtriptylineThe serum concentration of Fesoterodine can be increased when it is combined with Protriptyline.
PyridostigmineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Pyridostigmine.
PyrimethamineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pyrimethamine.
QuercetinThe serum concentration of Fesoterodine can be increased when it is combined with Quercetin.
QuetiapineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Quetiapine.
QuinacrineThe serum concentration of Fesoterodine can be increased when it is combined with Quinacrine.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Fesoterodine.
QuinidineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Quinidine.
QuinidineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Quinidine.
QuinineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Quinine.
RabeprazoleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rabeprazole.
RamosetronFesoterodine may increase the constipating activities of Ramosetron.
RanitidineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ranitidine.
RanolazineThe serum concentration of Fesoterodine can be increased when it is combined with Ranolazine.
ReboxetineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Reboxetine.
RegorafenibThe serum concentration of Fesoterodine can be increased when it is combined with Regorafenib.
RemifentanilThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Remifentanil.
ReserpineThe serum concentration of Fesoterodine can be decreased when it is combined with Reserpine.
RifabutinThe metabolism of Fesoterodine can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Fesoterodine can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Fesoterodine can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Fesoterodine can be increased when it is combined with Rilpivirine.
RisperidoneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Risperidone.
RitonavirThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ritonavir.
RivastigmineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rivastigmine.
RolapitantThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rolapitant.
RopiniroleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ropinirole.
RosiglitazoneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rosiglitazone.
RotigotineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rotigotine.
RutinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rutin.
SaquinavirThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fesoterodine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Scopolamine butylbromide.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Fesoterodine.
SelegilineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Selegiline.
SertralineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sertraline.
SildenafilThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sildenafil.
SiltuximabThe serum concentration of Fesoterodine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Fesoterodine can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Simvastatin.
SirolimusThe serum concentration of Fesoterodine can be decreased when it is combined with Sirolimus.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Fesoterodine.
SorafenibThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sorafenib.
SparteineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sparteine.
SpironolactoneThe serum concentration of Fesoterodine can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Fesoterodine can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Fesoterodine can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Fesoterodine can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Fesoterodine can be decreased when it is combined with Streptozocin.
SufentanilThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Sufentanil.
SulfanilamideThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sulfanilamide.
SulfaphenazoleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sulfaphenazole.
SulfinpyrazoneThe serum concentration of Fesoterodine can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Fesoterodine can be decreased when combined with Sulfisoxazole.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Fesoterodine.
SumatriptanThe serum concentration of Fesoterodine can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Fesoterodine can be increased when it is combined with Sunitinib.
TacrineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Tacrine.
TacrolimusThe serum concentration of Fesoterodine can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tamoxifen.
TapentadolThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tapentadol.
TapentadolThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Tapentadol.
Taurocholic AcidThe serum concentration of Fesoterodine can be increased when it is combined with Taurocholic Acid.
TegaserodThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tegaserod.
TelaprevirThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Telaprevir.
TelithromycinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Telithromycin.
TelmisartanThe serum concentration of Fesoterodine can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Temsirolimus.
TerazosinThe serum concentration of Fesoterodine can be increased when it is combined with Terazosin.
TerbinafineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Terbinafine.
TerfenadineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Terfenadine.
TesmilifeneThe serum concentration of Fesoterodine can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Fesoterodine can be increased when it is combined with Testosterone.
ThioridazineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Thioridazine.
ThiothixeneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Thiothixene.
TicagrelorThe serum concentration of Fesoterodine can be increased when it is combined with Ticagrelor.
TiclopidineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ticlopidine.
TiotropiumFesoterodine may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Fesoterodine.
TipranavirThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tipranavir.
TocilizumabThe serum concentration of Fesoterodine can be decreased when it is combined with Tocilizumab.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Fesoterodine.
TolvaptanThe serum concentration of Fesoterodine can be increased when it is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Topiramate.
TramadolThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tramadol.
TramadolThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Tramadol.
TranylcypromineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tranylcypromine.
TrazodoneThe serum concentration of Fesoterodine can be decreased when it is combined with Trazodone.
TrichlorfonThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Trichlorfon.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Fesoterodine.
TrifluoperazineThe serum concentration of Fesoterodine can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Fesoterodine can be increased when it is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Fesoterodine.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Fesoterodine.
TrimethoprimThe serum concentration of Fesoterodine can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Fesoterodine can be increased when it is combined with Trimipramine.
TripelennamineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tripelennamine.
TriprolidineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Triprolidine.
TroleandomycinThe serum concentration of Fesoterodine can be increased when it is combined with Troleandomycin.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Fesoterodine.
TrospiumThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Trospium.
TrospiumThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Trospium.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Fesoterodine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Fesoterodine.
UmeclidiniumThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Umeclidinium.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Fesoterodine.
VemurafenibThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Vemurafenib.
VenlafaxineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Venlafaxine.
VerapamilThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Verapamil.
VinblastineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Vinblastine.
VincristineThe serum concentration of Fesoterodine can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Vinorelbine.
VoriconazoleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Voriconazole.
YohimbineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Yohimbine.
ZafirlukastThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Zafirlukast.
ZimelidineThe serum concentration of Fesoterodine can be increased when it is combined with Zimelidine.
ZiprasidoneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ziprasidone.
Food Interactions
  • Take with or without food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Nilvebrant L: Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists. Pharmacol Toxicol. 2002 May;90(5):260-7. [PubMed:12076307 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Mansfield KJ, Chandran JJ, Vaux KJ, Millard RJ, Christopoulos A, Mitchelson FJ, Burcher E: Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther. 2009 Mar;328(3):893-9. doi: 10.1124/jpet.108.145508. Epub 2008 Nov 24. [PubMed:19029429 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Nilvebrant L: Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists. Pharmacol Toxicol. 2002 May;90(5):260-7. [PubMed:12076307 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Mansfield KJ, Chandran JJ, Vaux KJ, Millard RJ, Christopoulos A, Mitchelson FJ, Burcher E: Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther. 2009 Mar;328(3):893-9. doi: 10.1124/jpet.108.145508. Epub 2008 Nov 24. [PubMed:19029429 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Mansfield KJ, Chandran JJ, Vaux KJ, Millard RJ, Christopoulos A, Mitchelson FJ, Burcher E: Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther. 2009 Mar;328(3):893-9. doi: 10.1124/jpet.108.145508. Epub 2008 Nov 24. [PubMed:19029429 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Malhotra B, Guan Z, Wood N, Gandelman K: Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther. 2008 Nov;46(11):556-63. [PubMed:19000553 ]
  2. Malhotra B, Dickins M, Alvey C, Jumadilova Z, Li X, Duczynski G, Gandelman K: Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9. doi: 10.1111/j.1365-2125.2011.04007.x. [PubMed:21545485 ]
  3. Malhotra B, Sachse R, Wood N: Evaluation of drug-drug interactions with fesoterodine. Eur J Clin Pharmacol. 2009 Jun;65(6):551-60. doi: 10.1007/s00228-009-0648-1. Epub 2009 Apr 4. [PubMed:19347334 ]
  4. Malhotra BK, Wood N, Sachse R: Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. Int J Clin Pharmacol Ther. 2009 Sep;47(9):570-8. [PubMed:19761716 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Malhotra B, Guan Z, Wood N, Gandelman K: Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther. 2008 Nov;46(11):556-63. [PubMed:19000553 ]
  2. Malhotra B, Dickins M, Alvey C, Jumadilova Z, Li X, Duczynski G, Gandelman K: Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9. doi: 10.1111/j.1365-2125.2011.04007.x. [PubMed:21545485 ]
  3. Malhotra B, Sachse R, Wood N: Evaluation of drug-drug interactions with fesoterodine. Eur J Clin Pharmacol. 2009 Jun;65(6):551-60. doi: 10.1007/s00228-009-0648-1. Epub 2009 Apr 4. [PubMed:19347334 ]
  4. Malhotra BK, Wood N, Sachse R: Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. Int J Clin Pharmacol Ther. 2009 Sep;47(9):570-8. [PubMed:19761716 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Chancellor MB, Staskin DR, Kay GG, Sandage BW, Oefelein MG, Tsao JW: Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging. 2012 Apr 1;29(4):259-73. doi: 10.2165/11597530-000000000-00000. [PubMed:22390261 ]
Comments
comments powered by Disqus
Drug created on May 06, 2010 10:47 / Updated on October 01, 2016 02:23